Abstract
Extensive full-thickness defects remain challenging to reconstruct, as various techniques used, such as split-thickness skin grafts, often result in donor site morbidity and functional and cosmetic scar sequelae. This study evaluated the safety and efficacy of denovoSkin™—a bio-engineered autologous dermo-epidermal skin graft consisting of patient-derived epidermal and dermal cells cultured within an extracellular matrix—compared to autologous split thickness skin grafts (STSG). Twenty-three patients (mean age 37.4 years; 65% male; 70% post-burn scars), received both denovoSkin™ and STSG on comparable wound areas. At 3 months, scar quality was significantly better for denovoSkin™ than for STSG (POSAS observer total score 23.4 vs 27.9; p = 0.008), with benefits maintained at 12 months. Elasticity parameters also consistently favored denovoSkin™, and the ratio of covered surface area to donor site was markedly higher (8.5 vs 0.9; p < 0.001). DenovoSkin™ is a safe and effective treatment for full-thickness skin defects, providing favorable long-term skin quality.
Introduction
Extensive skin defects and scars from burns, trauma, congenital or acquired diseases, or former surgical procedures (like flap donor sites) pose a major reconstructive challenge. Common reconstructive techniques include split thickness skin grafts (STSG), full thickness skin grafts (FTSG), dermal templates, and various types of flaps. Each method comes with its own challenges: while STSGs are effective for epithelial coverage, healing may be accompanied by contractures and hypertrophic scarring, and donor sites may induce morbidity.1–3 Combining STSG with dermal templates may improve outcomes, though considerable scarring remains common. FTSGs and flaps can offer better outcomes but are limited by the availability and size of suitable donor tissue.
In recent decades, alternatives have been introduced such as cultured epithelial autografts (CEAs), whose use is limited by inconsistent graft take, mechanical fragility, and a tendency toward hypertrophic scarring.4–6 Next in line, dermal templates were developed to improve the outcome of deep dermal and full thickness wounds in terms of scarring.7–10 Advances in tissue engineering have enabled the development of dermo-epidermal skin grafts, containing both keratinocytes and dermal fibroblasts to better mimic full-thickness skin.11–17 Among these, denovoSkin™—an autologous, bi-layered engineered human skin graft with keratinocytes and fibroblasts—has shown promise in preclinical studies and early clinical applications.18,19 DenovoSkin™ is generated from patient’s own dermal fibroblasts and epidermal keratinocytes, cultured and expanded in vitro within an extracellular matrix (collagen hydrogel) to form a bilayer skin construct.
A phase I first-in-man open prospective, clinical trial in 2014 confirmed safety of denovoSkin™ in both pediatric and adult patients,20,21 and a phase II clinical trial in acute burn patients is presently ongoing (NCT03229564, NCT03227146; manuscript submitted (SB, personal communication). However, comparative data for reconstructive patients are not yet available, nor are data on long-term scar quality outcomes for reconstructive indications. Here, we report on a prospective, randomized, intra-patient controlled multicenter phase II study in reconstructive patients.
Methods
Study design
This phase II study was conducted to evaluate the efficacy and safety of an autologous bio-engineered dermo-epidermal skin graft, denovoSkin™, in comparison to autologous STSGs in patients undergoing planned elective scar reconstruction (trial ID NCT03394612). Patients were enrolled in three study sites in Italy (Santobono Pausilipon National Children’s Hospital, Napoli, AORN A. Cardarelli, Napoli and U.O.C Grandi Ustionati Azienda Ospedale University of Padova, Italy) two sites in The Netherlands (Red Cross Hospital, Beverwijk and Amsterdam University Medical Centers, location Vrije Universiteit, Amsterdam), and two sites in Switzerland (University Children’s Hospital Zurich, and University Hospital Zurich, Zurich, Switzerland). The study protocol closely aligned with the protocol of a previously approved clinical trial investigating denovoSkin™ in burn patients (trial ID NCT0322714, NCT03229564). The study protocol was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO; NL64565.000.18) and conducted in compliance with the ethical principles of the Declaration of Helsinki (2013), as well as the Good Clinical Practice (GCP) guidelines (ICH E6), the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), and any applicable local laws and regulations. Ethics committees and local authorities approved the study protocol. Written informed consent was obtained from each patient or their legally authorized representative before any study-related activities.
Participants
Eligible participants were patients (⩾1 years old) with full-thickness defects that required coverage in planned elective procedures. Inclusion and exclusion criteria are summarized in Table 1. The minimum wound area required was stratified by age category as follows: 9 (1–5 years), 25 (6–16 years), and 45 cm2 (>16 years). A sample size of 20 patients was calculated to provide 80% power to detect a statistically significant difference at a 5% significance level. Considering possible dropouts prior to assessment of the primary endpoint, this number was increased to 25.
Inclusion and exclusion criteria.
Study procedures
Production of denovoSkinTM
A split-thickness skin biopsy of approximately 4 cm2 was harvested from the patient requiring coverage of a full thickness defect, with an electric dermatome set at 0.2 mm. Autologous keratinocytes and fibroblasts were isolated and expanded in vitro. Subsequently, fibroblasts were incorporated into a bovine type I collagen hydrogel (Symatese, Chaponost, France), compressed and after a culture phase, keratinocytes were seeded on top to create the bi-layered dermo-epidermal skin graft denovoSkin™ . 21 The development and preclinical data on this construct were published earlier.11,12,14,22 After a production time of approximately 30 days, one or two pieces of denovoSkin™ (size 45 ± 4 cm2, thickness 0.5–2.0 mm) were shipped to the study sites in temperature-controlled conditions under Good Distribution Practice. Until February 2020, denovoSkin™ was manufactured in the GMP-certified clean room facility of Wyss Zurich, Zurich, Switzerland, and thereafter in the GMP-certified clean room facility of CUTISS AG, Schlieren, Switzerland. The production process is operating under GMP regulations involving in process controls, process validations and product release specifications. These include: graft’s integrity, geometry & thickness, cell count in graft, cells viability, histology and sterility.
Transplantation and follow-up
For each patient, two wound areas, each of maximal 90 cm2, were randomly allocated 1:1 to treatment with either denovoSkin™ or STSG. Randomization of study area treatment assignments was performed using software-based block randomization without stratification and documented in the electronic case report form (eCRF). To avoid bias in wound bed preparation procedures, randomization took place after completion of wound bed preparation. Skin defects were either excised (in case of tumor resection or flap donor site revision) or incised (in case of scar contractures). The wound bed was grafted with 1 or 2 grafts of denovoSkin™ (experimental area) and unmeshed or meshed up to 1:2 STSG (control area), taken with an electric dermatome set at 0.2 mm. The decision whether to mesh was left to the treating surgeon and based on clinical judgment of the wound bed, such as limited vascularization or anticipated exudation.
After transplantation, both study areas were dressed with Mepilex (Ag). Graft take of both study areas was assessed by an experienced clinician during the first dressing change, 6–10 days after grafting, and subsequently on day 21 and 28 after grafting. Throughout the wound healing process, both areas were treated similarly. Scar therapy mainly consisted of pressure garments and/or silicone therapy. Patients returned for follow-up visits at 2, 3, 6, and 12 months after grafting. At 3, 6, and 12 months, the Cutometer (MPA580, Courage Khazaka) was used to assess skin elasticity, the DSM II Colormeter (Cortex Technology) to assess skin color (erythema and melanin), and scar quality was assessed using the Patient and Observer Scar Assessment Scale (POSAS) version 2.0. 23 Photographic documentation of the study areas was performed at each visit. Adverse events, clinical laboratory results, and clinical and microbiological signs of infection were reported for safety assessment.
Study endpoints
Safety evaluation
Safety evaluation included signs of infection (6–10 days and 21 days post-grafting, assessed by a combination of clinical symptoms and bacterial culture results), adverse events for the full duration of the study, laboratory results, vital signs, and physical examination.
Primary efficacy endpoint
The primary endpoint was the scar quality of the study areas based on the POSAS observer scale total score (sum of items excluding overall opinion score), 3 months post-grafting. Higher total POSAS scores indicate worse scar quality, which is measured relative to the patient’s healthy skin.
Secondary efficacy endpoints
Secondary efficacy endpoints were wound healing characteristics (graft take, time to wound closure (⩾95% epithelialization)), scar elasticity parameters (Cutometer), scar color parameters (Colormeter), and POSAS patient- and observer scale items.
Statistical analysis
Continuous variables were summarized using descriptive statistics, while categorical variables were presented through frequency distributions. The difference in the primary efficacy endpoint (POSAS observer total score at 3 months) between the experimental and control area was analyzed by the two-sided paired t-test . For other outcomes assessed in both study areas, differences were similarly analyzed using two-sided paired t-tests. For Cutometer analyses, measurements with an R0 value of zero were excluded due to unreliability of the measurement. A p-value of <0.05 was considered statistically significant.
Results
Patient demographics
Between February 2018 and September 2024, a total of 24 patients underwent biopsy for denovoSkin™ manufacturing, and 23 patients proceeded to transplantation and were included in the final analysis (Figure 1). For one subject, the product could not be manufactured and the subject had to be withdrawn. Two patients dropped out after the grafting procedure; data collected up to their respective follow-ups was included in the analysis. Patient demographics and treatment characteristics are shown in Table 2. Of these patients, 16 (69.6%) were transplanted due to scar revision of a previous burn. Their mean initial total body surface area (TBSA) was 34.4% (SD 26.2%).
Flowchart of study participants.
Demographics and treatment characteristics in 23 patients.
The mean size of the biopsy for denovoSkin™ was 4.88 cm2, and the mean split-thickness skin donor area was 62.7 cm2. In most cases (20 out of 23, 87%), the control area was treated with an unmeshed STSG. In three patients (13%), a meshed STSG was used (expansion ratio 1:1.5 in two patients, 1:2 in one patient). The mean expansion ratio for denovoSkin™ was 8.5 (SD 4.4), and for STSG 0.9 (SD 0.22; p < 0.001). An example of the histological analysis (H&E staining) of a denovoSkin™ product at release is provided in Figure 2, showing the full construct dermis and epidermis.
Histological analysis (H&E staining) of the construct denovoSkin™ prior to transplantation.
Wound healing
Graft take was assessed between postoperative days 6 and 10 and was 69.8% (SD 31.8) in the denovoSkin™ area, compared to 85.0% (SD 14.5) in the STSG area (p = 0.053). Wound closure over time for denovoSkin™ areas and STSG is shown in Figure 3. Wounds were closed for two-thirds of patients after 56 days for denovoSkin™, and after 21 days for STSG. The difference in wound closure was statistically significant between treatment groups at 21, 28, and 56 days.
Number of patients with complete wound closure (⩾95% epithelialization) over time for denovoSkin™ (N = 22) and STSG (N = 22).
Safety evaluation
A safety evaluation was performed on data of 24 patients that underwent biopsy. An overview of (serious) adverse events that occurred during the study period is presented in Table 3. Over the total safety period, defined as the time between biopsy and end of the study (12 months post transplantation), a total of 57 events were reported for 17 patients, of which 18 events in 9 patients were serious. The most frequently reported adverse events were staphylococcal skin infections (29%) and scar contraction (17%). Infections in study areas occurred in six patients, two of these were in denovoSkin™ treated areas only (p = 0.157). Five patients (20.8%) experienced a total of seven events that were possibly related to denovoSkin™, which included infections (8.3%), excessive granulation tissue (4.2%), pruritus (4.2%), impaired healing (4.2%), and traumatic ulcer (4.2%). One of these events (impaired healing requiring additional surgery) was classified as serious, and two events in two patients (soft tissue neoplasm and impaired healing) lead to study discontinuation (after 1 week and after 1 month). No deaths were reported.
Overview of all (serious) adverse events reported during total safety period in 24 patients, including seriousness and possible relation to denovoSkin™.
Total safety period is defined as the time between first biopsy procedure and end of the study.
The bold text gives overall safety data, which are further specified in the rest of the table.
dS: denovoSkin™; n: number of patients; nae: number of adverse events;
Alopecia, eczema, skin pain, scar pain, skin swelling.
Serious adverse events are a subset of total adverse events.
Longitudinal clinical follow-up images of two patients are presented in Figure 4. Corresponding video documentation is available at 3 months for patient 1 (Supplemental Video, Supplemental Digital Content 1) and at 12 months for patient 2 (Supplemental Video, Supplemental Digital Content 2).
Longitudinal clinical follow-up of denovoSkin™ versus STSG in two patient requiring scar revision: (a) upper arm, scar incision and (b) forearm, scar excision.
Primary outcome – POSAS observer score at 3 months
A visual presentation of observer-rated scar quality items at 3 months is shown in Figure 5(a). At 3 months post-grafting, the mean observer total score was 23.4 (SD 10.0) for denovoSkin™ areas versus 27.9 (SD 9.5) for STSG areas (p = 0.008). In half of the cases (11 out of 21, 52%), denovoSkin™ areas were hypopigmented compared to normal skin. DenovoSkin™ significantly outperformed STSG for thickness (p = 0.031), relief (p < 0.001), pliability (p = 0.006), and overall opinion (p = 0.017) at 3 months. The detailed POSAS observer data at 3, 6, and 12 months post-burn are provided in Supplemental Table 1.
Mean POSAS observer (a and c) and patient (b and d) scores at 3 (upper) and 12 months (lower) post-grafting.
Other scar quality outcomes
POSAS observer score at 12 months
A visual comparison of observer-rated scar quality items at 12 months is shown in Figure 5(c). The mean observer total score was 18.5 (±7.6) for denovoSkin™ areas at 12 months post-grafting, versus 20.9 (±5.3) for STSG (p = 0.093). Significant differences in favor of denovoSkin™ were observed at 12 months for thickness (p = 0.030), relief (p = 0.002), and pliability (p = 0.049).
POSAS patient score
The detailed POSAS patient data at 3, 6, and 12 months post-burn are provided in Supplemental Table 2. A visual presentation of patient-rated scar quality items at 3 and 12 months is shown in Figure 5(b) and (d), respectively. At 3 months, the overall opinion on scar quality of both areas was rated as similar by patients (5.1 ± 2.9 for denovoSkin™ and 5.1 ± 2.5 for STSG). Color significantly differed between denovoSkin™ and STSG at 3 months (7.5 ± 1.9 vs 6.3 ± 2.8, p = 0.005). Patients preferred denovoSkin™ for stiffness (p < 0.05) and irregularity (p < 0.01).
Cutometer
Figure 6 shows maximum extension (Uf) values for denovoSkin™ and STSG at 3, 6, and 12 months post-grafting. The detailed Cutometer data are provided in Supplemental Table 3. Maximum extension (Uf) values were significantly better for denovoSkin™ at 3, 6, and 12 months post-grafting (p < 0.04).
Mean cutometer values (maximum extension (Uf)) in 20 patients for denovoSkin™ (blue) and STSG (orange) versus the values for the respective normal skin at 3, 6, and 12 months post-grafting.
Colormeter
The detailed Colormeter data are provided in Supplemental Table 4. No significant differences between the two areas were found at 3, 6, and 12 months post-grafting.
Discussion
We evaluated the safety and efficacy of the novel bio-engineered skin graft denovoSkin™ in patients requiring coverage of full thickness skin defects. DenovoSkin™ demonstrated statistically significant superior scar quality compared to STSG at 3 months, which was maintained at six and 12 months. In addition, denovoSkin™ achieved a markedly greater donor-site-to-surface ratio. No significant safety issues were encountered. These findings confirm that denovoSkin™ provides durable, high-quality skin coverage while minimizing donor site.
In reconstructive practice, FTSGs generally provide the most favorable functional and esthetic results; however, their use is severely limited by donor-site availability. DenovoSkin™ overcomes this limitation by offering skin coverage of full-thickness skin quality from a minimal biopsy. Thereby, denovoSkin™ provides stable coverage and significantly reduces donor-site morbidity – a major advantage for patients with extensive skin defects or those requiring multiple staged reconstructions. Preliminary observations in pediatric patients also suggest that denovoSkin™ may expand with growth, potentially reducing the need for secondary procedures later in life.
Over the past decades, several autologous bi-layered constructs containing fibroblasts and keratinocytes have been developed to improve outcomes in extensive wounds, such asself-assembled skin substitutes (SASSs) and engineered skin substitutes (ESSs). SASSs are generated by allowing fibroblasts to produce their own extracellular matrix in culture, onto which keratinocytes are subsequently seeded, whereas ESSs are composed of autologous fibroblasts and keratinocytes seeded on a biodegradable scaffold.24,25 Both have shown promising results in acute burn treatment, demonstrating stable wound closure, and reduced donor-site requirements in severely burned patients.24,26,27 However, such constructs have not yet been evaluated in controlled trials for reconstructive indications. Like these full skin constructs, denovoSkin™ contains autologous viable epidermal and dermal cells, which together with the compressed collagen component provides the essential structure for skin regeneration rather than scar formation. After a successful phase I study, a phase II study in adult and pediatric burn patients, and several compassionate use cases in acute burn treatment,18–21 the current study is the first to evaluate the safety and efficacy of denovoSkin™ on improving scar quality in reconstructive surgery.
Pigmentation remains a challenge in scars. The limited presence of melanocytes in the current composition of denovoSkin™ is reflected by the scores on the item pigmentation in the POSAS observer scale. DenovoSkin™ relies on peripheral pigment cell repopulation during graft maturation, 21 which explains the hypopigmented appearance of denovoSkin™. Nonetheless, we observed improvement of pigmentation over time, and re-introduction of melanocytes could be achieved by treatment of the hypopigmented areas using melanocyte spray techniques. 28 Preclinical developments have shown the feasibility of introducing melanocytes and even pre-vascularized structures in bioengineered skin constructs.15,22,29,30 Additionally, future developments might also extend to regeneration of hair follicles, sebaceous glands, and sweat glands.31,32 Such innovations are expected to further enhance functional and esthetic outcomes of bio-engineered skin constructs. An often-mentioned limitation of tissue-engineered skin is the manufacturing time. While relevant in acute settings, it is generally not an issue in reconstructive surgery. The biopsy-to-grafting interval is approximately 4 weeks, allowing for planned interventions, and cryopreservation of the autologous cells could even enable future re-use or delayed applications.
This study addresses several strengths and limitations. The intra-patient design allowed for direct comparison of the two treatment modalities under nearly identical wound environments, minimizing inter-subject variability. The long-term follow up and quantitative outcome evaluations in a multicenter trial setup are also strengths of this study, since these provide statistical power to the outcome analysis. This study also has some limitations. First, the sample size was relatively small, and although powered for the primary endpoint, it may not have been sufficient to detect smaller differences in secondary outcomes. Second, wound healing progression was assessed at predefined visits, therefore, progress between visits—for example, between day 28 and two months—may have gone unnoted, leading to the assessment of longer healing times. Nevertheless, the somewhat slower epithelialization of denovoSkin™ is likely due to the fact that it is produced submerged. Therefore, the epithelial differentiation is incomplete when applied to the wound and needs to be completed in situ after grafting (see Figure 2 for a histological image of the product prior to transplantation). In contrast, STSGs are already fully differentiated, and re-epithelialization occurs through cell migration from the edge of the meshes, resulting in faster wound closure. Also, denovoSkin™ requires neovascularization of the dermal component before full epithelization can be completed, similar to dermal templates. 33
Finally, one may question whether comparing denovoSkin™ to STSG represents the most appropriate comparison. FTSGs may more closely resemble the structure of denovoSkin™, however, the clinical applicability of FTSGs is limited due to high donor site constraints, especially in patients with large skin defects. Although the defects treated in this clinical trial were relatively modest in size, future use of denovoSkin™ in reconstruction would allow coverage of much larger defects. Also, STSGs remain commonly used, especially in burn reconstructive settings, where there is a limitation in donor sites for other reconstructive techniques, making these a relevant comparator in this trial.
Conclusion
This study demonstrates that denovoSkin™ is a safe and effective treatment modality for the reconstruction of full-thickness skin defects. Its ability to provide autologous, permanent, and full-thickness skin coverage makes it suitable for a broad range of indications, such as large full-thickness wounds, post-oncologic defects, contracture releases, traumatic injuries and chronic wound management. Significant advantages in scar quality—particularly in thickness, relief, pliability, elasticity and surface regularity—suggest that tissue-engineered skin substitutes may play a growing role in future reconstructive strategies.
Supplemental Material
sj-docx-1-tej-10.1177_20417314261429663 – Supplemental material for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial
Supplemental material, sj-docx-1-tej-10.1177_20417314261429663 for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial by Frederique M. Kemme, Anouk Pijpe, Matthea M. Stoop, Paul P. M. van Zuijlen, Martin Meuli, Clemens Schiestl, Fabienne Hartmann-Fritsch, Bong-Sung Kim, Kathrin Neuhaus, Jan A. Plock, Daniel Rittirsch, Kathi Mujynya, Ernst Reichmann, Sophie Böttcher-Haberzeth, Melinda Farkas, Jenny Bressan, Marcello Zamparelli, Ilaria Mataro, Carlo Petroccione, Alex Pontini, Bruno Azzena, Daniela Marino and Esther Middelkoop in Journal of Tissue Engineering
Supplemental Material
sj-docx-2-tej-10.1177_20417314261429663 – Supplemental material for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial
Supplemental material, sj-docx-2-tej-10.1177_20417314261429663 for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial by Frederique M. Kemme, Anouk Pijpe, Matthea M. Stoop, Paul P. M. van Zuijlen, Martin Meuli, Clemens Schiestl, Fabienne Hartmann-Fritsch, Bong-Sung Kim, Kathrin Neuhaus, Jan A. Plock, Daniel Rittirsch, Kathi Mujynya, Ernst Reichmann, Sophie Böttcher-Haberzeth, Melinda Farkas, Jenny Bressan, Marcello Zamparelli, Ilaria Mataro, Carlo Petroccione, Alex Pontini, Bruno Azzena, Daniela Marino and Esther Middelkoop in Journal of Tissue Engineering
Supplemental Material
sj-docx-3-tej-10.1177_20417314261429663 – Supplemental material for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial
Supplemental material, sj-docx-3-tej-10.1177_20417314261429663 for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial by Frederique M. Kemme, Anouk Pijpe, Matthea M. Stoop, Paul P. M. van Zuijlen, Martin Meuli, Clemens Schiestl, Fabienne Hartmann-Fritsch, Bong-Sung Kim, Kathrin Neuhaus, Jan A. Plock, Daniel Rittirsch, Kathi Mujynya, Ernst Reichmann, Sophie Böttcher-Haberzeth, Melinda Farkas, Jenny Bressan, Marcello Zamparelli, Ilaria Mataro, Carlo Petroccione, Alex Pontini, Bruno Azzena, Daniela Marino and Esther Middelkoop in Journal of Tissue Engineering
Supplemental Material
sj-docx-4-tej-10.1177_20417314261429663 – Supplemental material for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial
Supplemental material, sj-docx-4-tej-10.1177_20417314261429663 for Safety and efficacy of bio-engineered, autologous dermo-epidermal skin grafts in reconstructive surgery: 1-year results of a prospective, randomized, intra-patient controlled, multicenter phase II clinical trial by Frederique M. Kemme, Anouk Pijpe, Matthea M. Stoop, Paul P. M. van Zuijlen, Martin Meuli, Clemens Schiestl, Fabienne Hartmann-Fritsch, Bong-Sung Kim, Kathrin Neuhaus, Jan A. Plock, Daniel Rittirsch, Kathi Mujynya, Ernst Reichmann, Sophie Böttcher-Haberzeth, Melinda Farkas, Jenny Bressan, Marcello Zamparelli, Ilaria Mataro, Carlo Petroccione, Alex Pontini, Bruno Azzena, Daniela Marino and Esther Middelkoop in Journal of Tissue Engineering
Footnotes
Acknowledgements
We gratefully acknowledge the patients who participated in this study. The team of Wyss Zurich and CUTISS AG. are acknowledged for their many contributions before, during, and after manufacturing denovoSkin™. We thank the study coordinators, study nurses, and clinical and research team members at the participating centers for their dedication to the trial, and care for the patients.
ORCID iDs
Ethical considerations
The study protocol was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO; NL64565.000.18) and conducted in compliance with the ethical principles of the Declaration of Helsinki (2013), as well as the Good Clinical Practice (GCP) guidelines (ICH E6), the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), and any applicable local laws and regulations. Ethics committees and local authorities approved the study protocol.
Consent to participate
Written informed consent was obtained from each patient or their legally authorized representative before any study-related activities.
Consent for publication
Written informed consent for publication of the clinical images and videos was obtained from patients involved in this study.
Author contributions
All authors meet the ICMJE criteria for authorship. Each author has made a substantial contribution to the conception, design, data acquisition, or analysis of the study, has drafted or critically revised the manuscript, and has approved the final version for submission. All authors agree to be accountable for all aspects of the work.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was financed by Wyss Zurich and CUTISS AG.
Declaration of conflicting interests
The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The authors FMK, AP, MS, BSK, MF, JB, SB, KN and EM declare that they have no conflict of interest. Authors KM, CS and FHF are shareholders of CUTISS AG. Authors MM, DM, and ER are shareholders and board members, and PPMVZ is board member of CUTISS AG. (MM is President of the Board, DM is CEO). For the phase II clinical trials with denovoSkin™ (NCT03229564, NCT03227146, NCT03394612), author ER was the trial sponsor representative at University of Zurich (2017-2022), author CS was trial Coordinating Investigator, and authors EM, MM, SBH, BSK, JAP, DR, MZ, IM, and BA were trial principal investigators. Since April 2024, MM and EM are also trainers for CUTISS AG.
Data availability statement
The data from this clinical trial contain potentially identifying patient information. Public deposition would compromise patient privacy. The data that support the findings of this study are available from the corresponding author upon reasonable request.*
Supplemental material
Supplemental material for this article is available online.
Human rights
The study protocol was approved by the Dutch Central Committee on Research Involving Human Subjects (CCMO; NL64565.000.18).
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
